The anti-HIV treatment began to change radically with the introduction of the first protease inhibitor in 1995. Regimens combining protease inhibitors and reverse transcriptase inhibitors are the basis of (HAART) therapy for high efficiency, and which have improved survival and reduced survival of AIDS-related illnesses. Roche has also developed a reverse transcriptase inhibitor, an antiretroviral that has shown significantly prolong survival and reduce the onset of opportunistic infections. Cytomegalovirus Cytomegalovirus (CMV) infection is a common, normally inactive in individuals with healthy immune systems. The virus can become active in people with weakened immune systems, and whether it affects the eye, left untreated, can cause blindness. The effectiveness of HAART has reduced the number of people developing AIDS and thus the incidence of CMV infection. Despite this reduction, the commitment of Roche to people living with HIV and AIDS out for the future development of new treatments. In addition, Roche Diagnostics also offers a PCR test to measure the viral load of CMV, the sample of the Amplicor Monitor CMV.
Roche has developed a reverse transcriptase inhibitor, zalcitabine, a protease inhibitor, saquinavir and commercializes the protease inhibitor used in the world, nelfinavir. He has also developed standard ganciclovir treatment of an opportunistic infection common in people with advanced HIV infection, CMV retinitis (CMV).